News Poolbeg expects first data for CRS drug in the summer A trial to see if Poolbeg's POLB-001 can prevent cytokine release syndrome in multiple myeloma treated with immunotherapy Tecvayli will start soon.
News Lilly trumpets strong result for Jaypirca in CLL at EHA New data with Eli Lilly's Jaypirca at EHA 2026 has cemented its place as a second-line therapy for chronic lymphocytic leukaemia.
News Data could move J&J's Talvey earlier in myeloma therapy Johnson & Johnson's Talvey looks set to move second-line in multiple myeloma treatment, based on the results of the MonumenTAL-3 trial at EHA 2026.
News AZ's Truqap and Roche assay cleared for PTEN prostate cancer AstraZeneca has claimed a second approval for AKT inhibitor Truqap, in prostate cancer, that should help achieve its blockbuster hopes for the drug.
News Moderna jab on trial for cancer-causing syndrome Patients with Lynch syndrome could have a potential treatment on the horizon, as a Moderna mRNA vaccine starts trials at Oxford University.
News GSK pursues $10.6bn takeover of cancer biotech Nuvalent GSK is preparing for its biggest acquisition in more than 10 years, agreeing to buy cancer drug developer Nuvalent for $10.6 billion.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.